185 related articles for article (PubMed ID: 34309232)
1. DYRK1A activates NFATC1 to increase glioblastoma migration.
Liu H; Sun Q; Chen S; Chen L; Jia W; Zhao J; Sun X
Cancer Med; 2021 Sep; 10(18):6416-6427. PubMed ID: 34309232
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Pozo N; Zahonero C; Fernández P; Liñares JM; Ayuso A; Hagiwara M; Pérez A; Ricoy JR; Hernández-Laín A; Sepúlveda JM; Sánchez-Gómez P
J Clin Invest; 2013 Jun; 123(6):2475-87. PubMed ID: 23635774
[TBL] [Abstract][Full Text] [Related]
3. NFATc1 phosphorylation by DYRK1A increases its protein stability.
Liu H; Wang K; Chen S; Sun Q; Zhang Y; Chen L; Sun X
PLoS One; 2017; 12(2):e0172985. PubMed ID: 28235034
[TBL] [Abstract][Full Text] [Related]
4. NFATc1 activation promotes the invasion of U251 human glioblastoma multiforme cells through COX-2.
Wang L; Wang Z; Li J; Zhang W; Ren F; Yue W
Int J Mol Med; 2015 May; 35(5):1333-40. PubMed ID: 25738651
[TBL] [Abstract][Full Text] [Related]
5. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
[TBL] [Abstract][Full Text] [Related]
6. p53 downregulates Down syndrome-associated DYRK1A through miR-1246.
Zhang Y; Liao JM; Zeng SX; Lu H
EMBO Rep; 2011 Jun; 12(8):811-7. PubMed ID: 21637297
[TBL] [Abstract][Full Text] [Related]
7. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
[TBL] [Abstract][Full Text] [Related]
8. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
[TBL] [Abstract][Full Text] [Related]
9. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
[TBL] [Abstract][Full Text] [Related]
10. DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Chen B; McCuaig-Walton D; Tan S; Montgomery AP; Day BW; Kassiou M; Munoz L; Recasens A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33924599
[TBL] [Abstract][Full Text] [Related]
11. Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Lee Y; Ha J; Kim HJ; Kim YS; Chang EJ; Song WJ; Kim HH
J Biol Chem; 2009 Nov; 284(48):33343-51. PubMed ID: 19801542
[TBL] [Abstract][Full Text] [Related]
12. DYRK1A-mediated PLK2 phosphorylation regulates the proliferation and invasion of glioblastoma cells.
Tan S; Zhao J; Wang P
Int J Oncol; 2023 Aug; 63(2):. PubMed ID: 37387444
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
[TBL] [Abstract][Full Text] [Related]
14. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
15. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
16. Bidirectional Regulation between NDRG1 and GSK3β Controls Tumor Growth and Is Targeted by Differentiation Inducing Factor-1 in Glioblastoma.
Ito H; Watari K; Shibata T; Miyamoto T; Murakami Y; Nakahara Y; Izumi H; Wakimoto H; Kuwano M; Abe T; Ono M
Cancer Res; 2020 Jan; 80(2):234-248. PubMed ID: 31723002
[TBL] [Abstract][Full Text] [Related]
17. DYRK1A kinase inhibitors with emphasis on cancer.
Ionescu A; Dufrasne F; Gelbcke M; Jabin I; Kiss R; Lamoral-Theys D
Mini Rev Med Chem; 2012 Nov; 12(13):1315-29. PubMed ID: 23016545
[TBL] [Abstract][Full Text] [Related]
18. Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.
Mao P; Hever-Jardine MP; Rahme GJ; Yang E; Tam J; Kodali A; Biswal B; Fadul CE; Gaur A; Israel MA; Spinella MJ
PLoS One; 2013; 8(11):e81803. PubMed ID: 24312360
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro.
Bernhart E; Damm S; Wintersperger A; DeVaney T; Zimmer A; Raynham T; Ireson C; Sattler W
Exp Cell Res; 2013 Aug; 319(13):2037-2048. PubMed ID: 23562655
[TBL] [Abstract][Full Text] [Related]
20. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
